Vicore Pharma Holding Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Public

  • Employees
  • 40

Employees

  • Stock Symbol
  • VICO

Stock Symbol

  • Investments
  • 5

  • Share Price
  • $1.07
  • (As of Friday Closing)

Vicore Pharma Holding General Information

Description

Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Kornhamnstorg 53
  • 111 27 Stockholm
  • Sweden
+46 031-788
Primary Industry
Drug Discovery
Stock Exchange
STO
Vertical(s)
Corporate Office
  • Kornhamnstorg 53
  • 111 27 Stockholm
  • Sweden
+46 031-788

Vicore Pharma Holding Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Vicore Pharma Holding Stock Performance

As of 13-Nov-2026, Vicore Pharma Holding’s stock price is $1.07. Its current market cap is $301M with 282M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.07 $1.10 $0.86 - $1.89 $301M 282M 1.12M -$0.20

Vicore Pharma Holding Financials Summary

As of 30-Sep-2026, Vicore Pharma Holding has a trailing 12-month revenue of $407K.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 179,206 255,327 145,532 103,335
Revenue 407 389 10,339 0
EBITDA (58,790) (51,025) (17,750) (29,959)
Net Income (55,818) (48,599) (15,945) (29,254)
Total Assets 82,008 132,433 108,359 49,814
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Vicore Pharma Holding Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Vicore Pharma Holding‘s full profile, request access.

Request a free trial

Vicore Pharma Holding Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying thera
Drug Discovery
Stockholm, Sweden
40 As of 2026

Yardley, PA
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Vicore Pharma Holding Competitors (7)

One of Vicore Pharma Holding’s 7 competitors is Savara, a Formerly VC-backed company based in Yardley, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Savara Formerly VC-backed Yardley, PA
Avalyn Pharma Formerly VC-backed Boston, MA
Gilead Formerly VC-backed Foster City, CA
Biogen Formerly VC-backed Cambridge, MA
Amgen Formerly PE-Backed Thousand Oaks, CA
You’re viewing 5 of 7 competitors. Get the full list »

Vicore Pharma Holding Patents

Vicore Pharma Holding Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2019263701-A1 New treatment of interstitial lung diseases Inactive 03-May-2018
CA-3099008-A1 New treatment of interstitial lung diseases Inactive 03-May-2018
EP-3787599-A1 New treatment of interstitial lung diseases Inactive 03-May-2018
US-20210236425-A1 New treatment of interstitial lung diseases Inactive 03-May-2018
WO-2019211624-A1 New treatment of interstitial lung diseases Inactive 03-May-2018 A61K9/143
To view Vicore Pharma Holding’s complete patent history, request access »

Vicore Pharma Holding Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vicore Pharma Holding Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Vicore Pharma Holding‘s full profile, request access.

Request a free trial

Vicore Pharma Holding Investments & Acquisitions (5)

Vicore Pharma Holding’s most recent deal was a Corporate Asset Purchase with HaLaCore (Pipeline of Novel Preclinical-Stage AT2R Agonists) for . The deal was made on 02-Nov-2020.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
HaLaCore (Pipeline of Novel Preclinical-Stage AT2R Agonists) 02-Nov-2020 Corporate Asset Purchase Buildings and Property
INIM Pharma 20-Aug-2018 Merger/Acquisition Drug Discovery
I-Tech (Molndal) 08-Feb-2018 Later Stage VC Industrial Chemicals
I-Tech (Molndal) 01-Mar-2011 Later Stage VC Industrial Chemicals
I-Tech (Molndal) 01-Jan-2000 Early Stage VC Industrial Chemicals
To view Vicore Pharma Holding’s complete investments and acquisitions history, request access »

Vicore Pharma Holding ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

25.19 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,585

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Vicore Pharma Holding’s complete esg history, request access »

Vicore Pharma Holding Exits (3)

Vicore Pharma Holding’s most recent exit was on 08-Feb-2018 from I-Tech (Molndal). The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
I-Tech (Molndal) 08-Feb-2018 Completed
I-Tech (Molndal) 01-Mar-2011 Completed
  • 4 buyers
I-Tech (Molndal) 01-Jan-2000 Early Stage VC Completed
  • 2 buyers
To view Vicore Pharma Holding’s complete exits history, request access »

Vicore Pharma Holding Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
INIM Pharma Sweden 2018

Vicore Pharma Holding FAQs

  • When was Vicore Pharma Holding founded?

    Vicore Pharma Holding was founded in 2000.

  • Where is Vicore Pharma Holding headquartered?

    Vicore Pharma Holding is headquartered in Stockholm, Sweden.

  • What is the size of Vicore Pharma Holding?

    Vicore Pharma Holding has 40 total employees.

  • What industry is Vicore Pharma Holding in?

    Vicore Pharma Holding’s primary industry is Drug Discovery.

  • Is Vicore Pharma Holding a private or public company?

    Vicore Pharma Holding is a Public company.

  • What is Vicore Pharma Holding’s stock symbol?

    The ticker symbol for Vicore Pharma Holding is VICO.

  • What is the current stock price of Vicore Pharma Holding?

    As of 13-Nov-2026 the stock price of Vicore Pharma Holding is $1.07.

  • What is the current market cap of Vicore Pharma Holding?

    The current market capitalization of Vicore Pharma Holding is $301M.

  • What is Vicore Pharma Holding’s current revenue?

    The trailing twelve month revenue for Vicore Pharma Holding is $407K.

  • Who are Vicore Pharma Holding’s competitors?

    Savara, Avalyn Pharma, Gilead, Biogen, and Amgen are some of the 7 competitors of Vicore Pharma Holding.

  • What is Vicore Pharma Holding’s annual earnings per share (EPS)?

    Vicore Pharma Holding’s EPS for 12 months was -$0.20.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process